Eyob Tessema, MD
Psychiatry · Enterprise, ALNPI 1639195076
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 377 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations.
Across 377 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$927
- Vanda Pharmaceuticals Inc.$477
- Teva Pharmaceuticals USA, Inc.$451
- Corium, LLC$430
- Takeda Pharmaceuticals U.S.A., Inc.$405
- plus $3K from 17 others
What the payments were for
- Food & beverage$6,23499%
- Education$911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 63 | $1,047 |
| AbbVie(2 entities) | 67 | $927 |
| Vanda Pharmaceuticals Inc. | 26 | $477 |
| Teva Pharmaceuticals USA, Inc. | 24 | $451 |
| Corium, LLC | 19 | $430 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $405 |
| Idorsia Pharmaceuticals US Inc | 19 | $369 |
| Alkermes, Inc. | 18 | $337 |
| Sunovion Pharmaceuticals Inc. | 29 | $260 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $213 |
| Neurocrine Biosciences, Inc. | 8 | $204 |
| Axsome Therapeutics, Inc. | 10 | $192 |
| Tris Pharma Inc | 16 | $192 |
| Ironshore Pharmaceuticals Inc. | 10 | $185 |
| Lundbeck LLC | 7 | $128 |
| Supernus Pharmaceuticals, Inc. | 5 | $117 |
| Almatica Pharma LLC | 5 | $95 |
| Merck | 5 | $85 |
| Eisai Inc. | 4 | $62 |
| Collegium Pharmaceutical, Inc. | 3 | $54 |
| Shire North American Group Inc | 3 | $50 |
| Johnson & Johnson | 2 | $35 |
| Neos Therapeutics, LP | 1 | $13 |
How this compares
$6,325 in reported general payments places this provider in the 85th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 21 | $210,728 |
| Invega SustennaPaliperidone Palmitate | 41 | $127,113 |
| RexultiBrexpiprazole | 52 | $116,458 |
| NuedextaDextromethorphan Hbr/Quinidine | 41 | $65,254 |
| VraylarCariprazine Hcl | 43 | $57,426 |
| TrintellixVortioxetine Hydrobromide | 92 | $51,233 |
| Abilify MaintenaAripiprazole | 18 | $48,001 |
| CaplytaLumateperone Tosylate | 25 | $42,223 |
| Aripiprazole | 141 | $18,030 |
| Clomipramine Hcl | 49 | $11,882 |
| Oxcarbazepine | 150 | $11,438 |
| Paliperidone ErPaliperidone | 21 | $7,319 |
| Vilazodone Hcl | 40 | $6,951 |
| BelsomraSuvorexant | 14 | $6,029 |
| Lamotrigine OdtLamotrigine | 12 | $5,314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $451 | $210,72821 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,047 | $164,45970 claims |
| Johnson & JohnsonInvega Sustenna | $35 | $127,11341 claims |
| AbbVieVraylar | $927 | $57,42643 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $405 | $51,23392 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $213 | $42,22325 claims |
| MerckBelsomra | $85 | $6,02914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Enterprise
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Scariya KumaramangalamHuntsville$440K
- Mark HaygoodMobile$348K
- Lori DavisTuscaloosa$161K
- Bradley SadlerMobile$124K
- Brandi Rudolph BollingJasper$97K
- Richard SheltonBirmingham$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.